Zepbound at 3 months: the label does not measure it there

What the label measures, and when

Four trials sit behind the weight indication, and every one of them was built around a long run. Studies 1, 2 and 3 assessed weight after 72 weeks of treatment, with at least 52 of those weeks at the maintenance dose. Study 4 ran an open-label 36-week lead-in and then a randomized withdrawal out to week 88.

The label does draw the weeks in between. Figures 3 through 6 plot weight against time from the first dose, but they are pictures printed in the document with no table beside them, so no twelve-week value can be read off them and none is quoted here. The by-dose results at week 72 are set out in full on Zepbound at 5, 10 and 15 mg.

Where the label's own schedule puts you at 12 weeks

There is a second reason the label has nothing to say at three months: on its own schedule, most people are not yet on a dose the label calls a maintenance dose.

Treatment starts at 2.5 mg once weekly for four weeks, which the label states is “for treatment initiation and is not approved as a maintenance dosage”. After four weeks the dosage goes to 5 mg, and from there it “may be increased in 2.5 mg increments, after at least 4 weeks on the current dose”. At the fastest the label allows, that puts a patient on 7.5 mg through weeks 9 to 12 — the third dosage of six, two steps below the top. In the trials themselves, escalation ran “over a period of up to 20 weeks” before the maintenance period began.

So the first three months are, by the label’s own design, the climb rather than the plateau. The four products’ ladders sit side by side on the dose escalation schedules, and what the labels report about side effects during that climb is on side effect rates, label by label.

The one 12-week number in the document

One twelve-week figure does appear in the label, and it is not a Zepbound result. Study 3 opened with a 12-week intensive lifestyle program before any drug: eight sessions with a dietitian, a target of 1,200 kcal a day for women and 1,500 for men, and at least 150 minutes of exercise a week. The 579 patients who went on to be randomized had lost an average of 6.9% of their body weight by the end of it.

That is what the label reports for twelve weeks of anything. Only patients who lost at least 5% during those weeks entered the drug phase, so the figure describes a selected group, and the 18.4% they went on to lose over the next 72 weeks is measured from the day the drug started, not from the day they walked in.

Sources

See the providers

What a month of treatment costs is a separate question from what it does. The boards list who sells tirzepatide and what each seller publishes about the price.

• Tirzepatide providersprovider board

  Readers who have settled on tirzepatide and are choosing who to buy it from.

• Semaglutide providersprovider board

  Readers who have settled on semaglutide and are choosing who to buy it from.

More, read from the same labels

• Semaglutide vs tirzepatidereading the label

  What the four FDA-approved labels say each molecule is, what each is approved to treat, and where the two differ.

• How they workreading the label

  The receptor each molecule switches on, what the labels say that does to appetite, blood sugar and the stomach, and why one dose lasts a week.

• Is Ozempic insulin?reading the label

  What the Ozempic label calls semaglutide, how that differs from insulin, and where insulin appears on these labels as a separate medicine.

• Zepbound vs Ozempicreading the label

  Four brand names, two molecules and two kinds of approval: which of these products are the same drug, and what each one is actually approved to do.

• Dose escalation schedulesreading the label

  The starting dose, the escalation interval and the maximum dose each label sets, and why they are not interchangeable.

• Side effect ratesreading the label

  What each label reports for nausea, vomiting, diarrhea and constipation — and the sentence every label prints above those numbers.

• Hair lossreading the label

  Which labels report hair loss, the rate against placebo where a trial measured it, and why two of them put no number on it.

• Fatigue and tirednessreading the label

  Which labels list fatigue, the rate against placebo where a trial measured it, and what each label counts as fatigue.

• Missed dose rulesreading the label

  The window each label gives for a late dose, and the minimum gap it requires when the injection day changes.

• Drug interactionsreading the label

  Insulin and sulfonylureas, oral medications, and the oral-contraceptive precaution that appears on two of these four labels and not the other two.

• Buying one onlinereading the label

  The agency's own warning signs for a telehealth GLP-1 seller, its 28-day vial rule, and what it says about drugs that arrive warm.

• Zepbound by dosereading the label

  What each Zepbound dose achieved in the trials printed in its label, what the label says about choosing a maintenance dose, and what the higher doses cost in side effects.

• Injecting tirzepatidereading the label

  The injection sites, the rotation rule and the steps for the single-dose pen, the KwikPen and the vial and syringe, exactly as the FDA-approved Instructions for Use give them.

• Refrigeration and storagereading the label

  How cold each pen is kept, how many days it can spend at room temperature, and what the labels say about heat and freezing.

• Who should not take onereading the label

  The boxed warning every one of these labels carries, the two contraindications, and which warnings appear on which product.